$ICPT. I agree that some good results are baked in but think the initial indication could bring in real revenue, and the NASH indication is massive. If they hit on NASH, $3B is nothing. Compare that to the many start-ups now valued over $1.5B, with many 4+ yrs from any solid revenue, and small indications in clinic
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.